Evolva aligns synthetic biology luminaries, funding, and access to commercialization resources

Evolva has had a string of recent announcements: last month, we reported Evolva's acquisition of R&D partner Abunda Nutrition (see the August 9, 2011 LRMCJ). Now comes a series of developments within several weeks: first, Jay Keasling (co-founder of Amyris, who engineered fermentative production of ...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Manus Bio

Company Snapshot | March 25, 2021

The company was founded by Ajikumar Parayil and Prof. Gregory Stephanopoulos; Ajikumar is currently the CEO of the company, and Gregory continues to serve as a board member; as of 2021, the company has close to 78 employees. To date, the company has raised approximately $95 million, with the most ... Not part of subscription

Global Bioenergies to launch its own range of cosmetic products

News Commentary | April 29, 2021

Global Bioenergies has been shifting its focus to high‑margin applications in recent years. The biotech startup now plans to produce and market a line of makeup products using its own bio‑based ingredient. It will initially produce 300,000 units and aims to have its commercial launch in the next six... Not part of subscription

Manus Bio

Company Profile | March 17, 2022

Develops specialty ingredients through microbial fermentation; over the past two years, the company has focused on developing its integrated technology platform, BioAssemblyLine, which encompasses metabolic engineering, protein engineering, and systems biology approaches to engineer microbes that... Not part of subscription